Last update 04 Nov 2024

Donepezil Hydrochloride

Last update 04 Nov 2024

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

SummaryDonepezil, a minuscule molecular compound, functions as an acetylcholinesterase inhibitor, indicating that it hinders the degradation of acetylcholine, a neurotransmitter in the brain, and provides assistance in enhancing cognitive function. Patients in mild, moderate, and severe stages of Alzheimer's Disease receive this drug as a therapeutic agent. Initially authorized in November 1996 by Eisai, a pharmaceutical establishment situated in Japan, it has now expanded to a worldwide availability. Although Donepezil Hydrochloride does not hold the cure for Alzheimer's Disease, it does assist in controlling some of the symptoms associated with the disease, such as memory loss, confusion, and other cognitive impairments. As a crucial medication for those existing with Alzheimer's Disease, it can amplify their quality of life and curtail the progression of the disease.

Drug Type

Small molecule drug

Synonyms

ARIPEZIL, BNAG, Domepezil

+ [44]

Target

AChE

Mechanism

AChE inhibitors(Acetylcholinesterase inhibitors)

Therapeutic Areas

Nervous System DiseasesEndocrinology and Metabolic DiseaseOther Diseases

Active Indication

Lewy Body DiseaseAlzheimer DiseaseDementia+ [1]

Inactive Indication

Advanced cancerAttention Deficit DisorderCognitive Dysfunction+ [9]

Originator Organization

Eisai Co., Ltd.

Active Organization

Eisai Co., Ltd.

Eisai, Inc.

Aulbio Co., Ltd.Startup

+ [11]

Inactive Organization

Teva Pharmaceuticals USA, Inc.

Pfizer Inc.

Teikoku Pharma USA, Inc.

+ [2]

Drug Highest PhaseApproved

First Approval Date

US (25 Nov 1996),

Alzheimer Disease

RegulationPriority Review (CN)

Structure

Molecular FormulaC24H30ClNO3

InChIKeyXWAIAVWHZJNZQQ-UHFFFAOYSA-N

CAS Registry120011-70-3

358

Clinical Trials associated with Donepezil Hydrochloride

NCT06041789 / RecruitingPhase 2IIT

Effect of Acetylcholinesterase Inhibitors on Bone Metabolism and Fracture Risk Factors Among Older Adults With Mild to Moderate Alzheimer's Disease

People with Alzheimer's disease are at an increased risk of bone fracture. Some studies have shown that those taking donepezil have a lower rate of bone fractures, but the reasons for this are unknown. The purpose of this study is to measure the effect of donepezil treatment on bone metabolism factors including bone mineral density, bone turnover markers, and bone quality.
Participants in this study will have a bone density test and have blood samples collected at the baseline study visit. Participants will then be randomly assigned to donepezil or matching placebo to be taken daily by mouth for 12 months. Blood samples will be collected at 6 and 12 months. A repeat bone density test will be performed at 12 months. Participants will also complete questionnaires at each study visit.

Start Date01 Oct 2024

Sponsor / Collaborator

Duke University

[+1]

NCT05592678 / Not yet recruitingNot ApplicableIIT

Novel Methods for Clinical Trials in Dementia and Cognitive Decline

The goal of this clinical trial is to demonstrate potential improvements in clinical trial methods relating to dementia and cognitive decline. The main questions it aims to answer are:
* Can an intervention's outcome be better assessed by a latent variable ("δ") integrating cognitive performance with functional status?
* Can latent biomarkers of δ guide the selection of an intervention that will modulate dementia severity?
* Can a latent variable, derived from information collected remotely from caregivers, preselect subjects most likely to respond to the intervention?
* Is the effect of the intervention in fact medicated by changes in the targeted biomarker?
In this case, the biomarker will be a latent variable derived from several proteins measured in blood (i.e., so-called "adipokines"). The intervention will be donepezil, a medication approved for the treatment of Alzheimer's Disease, but only recently associated with adipokine changes.
Participants with cognitive impairment and their caregivers will be interviewed by telephone and those newly prescribed donepezil by their provider for cognitive impairment will be recruited and enrolled. On the basis of the caregiver's report, the cognitively impaired subjects will be assigned to two groups based on a prediction of their response to donepezil. Researchers will compare those groups to see if dementia severity, as measured by δ, improves in predicted responders, and whether the change in the d-score is mediated by changes in adipokines.

Start Date01 Oct 2024

Sponsor / Collaborator

University of Texas Health Science Center At San Antonio

[+1]

CTR20242532 / Active, not recruitingNot Applicable

盐酸多奈哌齐口崩片人体生物等效性研究

[Translation] Study on the bioequivalence of donepezil hydrochloride orodisintegrating tablets in healthy volunteers

本试验旨在研究健康研究参与者单次空腹和餐后口服山东淄博新达制药有限公司生产的盐酸多奈哌齐口崩片（5 mg）的药代动力学特征；以日本卫材株式会社生产的盐酸多奈哌齐口崩片（Aricept® D，5 mg）为参比制剂，比较两制剂中药动学参数Cmax和AUC0-72，评价两制剂的人体生物等效性，并观察两制剂在健康研究参与者中的安全性。

[Translation]

This study aimed to investigate the pharmacokinetic characteristics of donepezil hydrochloride orodisintegrating tablets (5 mg) produced by Shandong Zibo Xinda Pharmaceutical Co., Ltd. in healthy study participants after single fasting and postprandial oral administration; using donepezil hydrochloride orodisintegrating tablets (Aricept® D, 5 mg) produced by Eisai Co., Ltd. as the reference preparation, to compare the pharmacokinetic parameters Cmax and AUC0-72 of the two preparations, to evaluate the bioequivalence of the two preparations in humans, and to observe the safety of the two preparations in healthy study participants.

Start Date09 Aug 2024

Sponsor / Collaborator

Shandong Zibo Xincat Pharmaceutical Co., Ltd.

100 Clinical Results associated with Donepezil Hydrochloride

100 Translational Medicine associated with Donepezil Hydrochloride

100 Patents (Medical) associated with Donepezil Hydrochloride

4,772

Literatures (Medical) associated with Donepezil Hydrochloride

01 Feb 2025·Pharmaceutical nanotechnology

Optimizing Neuroprotective Nano-structured Lipid Carriers for Transdermal Delivery through Artificial Neural Network

Article

Author: Prajapati, Bhupendra ; Dalwadi, Saloni ; Thakkar, Vaishali

Background::

Dementia associated with Alzheimer’s disease (AD) is a neurological disorder. AD is a progressive neurodegenerative condition that predominantly impacts the elderly population, although it can also manifest in younger people through the impairment of cognitive functions, such as memory, cognition, and behaviour. Donepezil HCl and Memantine HCl are encapsulated in Nanostructured Lipid Carriers (NLCs) to prolong systemic circulation and minimize the systemic side effects.

Objective::

This work explores the use of data mining tools to optimize the formulation of NLCs comprising of Donepezil HCl and Memantine HCl for transdermal drug delivery. Neuroprotective drugs and excipients are utilized for protecting the nervous system against damage or degeneration.

Method::

The NLCs were formulated using a high-speed homogenization technique followed by ultrasonication. NLCs were optimized using Box Behnken Design (BBD) in Design Expert Software and artificial neural network (ANN) in IBM SPSS statistics. The independent variables included the ratio of solid lipid to liquid lipid, the percentage of surfactant, and the revolutions per minute (RPM) of the high-speed homogenizer.

Results::

The NLCs that were formulated had a mean particle size ranging from 67.0±0.45 to 142.4±0.52 nm. Both drugs have a %EE range over 75%, and Zeta potential was determined to be - 26±0.36 mV. CryoSEM was used to do the structural study. The permeation study showed the prolonged release of the formulation.

Conclusion::

The results indicate that NLCs have the potential to be a carrier for transporting medications to deeper layers of the skin and reaching systemic circulation, making them a suitable formulation for the management of Dementia. Both ANN and BBD techniques are effective tools for systematically developing and optimizing NLC formulation.

01 Jan 2025·ARCHIVES OF GERONTOLOGY AND GERIATRICS

Risk of antimuscarinic initiation with cholinesterase inhibitor use in Alzheimer's disease

Article

Author: Aparasu, Rajender R. ; Chikermane, Soumya G ; Li, Jieni ; Aparasu, Rajender R ; Chikermane, Soumya G.

BACKGROUND:

The use of cholinesterase inhibitors (CHEIs) is commonly associated with urinary incontinence in patients with Alzheimer's disease (AD). This study evaluated the risk of antimuscarinic initiation drugs with the use of CHEIs in AD patients.

METHODS:

The study used a nested case-control study design involving 2013-2015 Medicare data of AD patients 65 years and older without antimuscarinic use in 2013. Cases were defined as those who initiated antimuscarinic treatment in 2014-2015. Controls with no antimuscarinic use were selected through incidence density sampling and matched to cases on age using a variable-ratio method. The CHEI utilization pattern was classified as current (event-30 days), recent (event-31 to event-90 days), and past (event-91 to event-180 days). Conditional logistic regression was used to assess the association between CHEI use and the risk of antimuscarinic initiation.

RESULTS:

This study included 1,909 cases and 9,064 controls. The adjusted model found that overall CHEI (Adjusted Odds Ratio [aOR] = 1.90, 95 % Confidence Interval [CI]: 1.58-2.28) and current CHEI use (aOR = 1.62, 95 % CI: 1.18-2.21) were associated with an increase in the risk of antimuscarinic initiation compared to non-CHEI use. In addition, the current use of donepezil and rivastigmine significantly increased the risk of antimuscarinic initiation by 48 % (95 % CI: 1.03-2.12) and 171 % (95 % CI: 1.46-5.03), respectively.

CONCLUSION:

The study found an increased risk of antimuscarinic initiation with the current use of CHEIs, particularly with donepezil and rivastigmine. These findings underscore the need for careful medication management to minimize prescribing cascades and associated consequences in AD.

01 Jan 2025·JOURNAL OF ETHNOPHARMACOLOGY

Ameliorative potential of ethanol extract of Calyptrochilum emarginatum leaves on scopolamine-induced amnesia in male swiss mice

Article

ETHNOPHARMACOLOGICAL RELEVANCE:

Calyptrochilum emarginatum (Afzel. Ex Sw.) Schltr. (Orchidaceae) is a traditional medicinal plant known for its antimicrobial properties and efficacy in managing convulsive fever and menstrual disorders and addressing conditions such as malaria, tuberculosis, and cough.

AIM OF THE STUDY:

The study aims to examine the memory-enhancing and neuroprotective properties of ethanol extract of Calyptrochilum emarginatum leaves (EECEL) in scopolamine-induced amnesia mice model.

MATERIALS AND METHODS:

Forty-two male mice were divided into six groups (n = 7). Group 1 served as control, administered distilled water (10 mL/kg, p. o), group 2 received scopolamine only (3 mg/kg, i. p.), groups 3 to 6 received pretreatments of EECEL (50, 100, and 200 mg/kg, p. o.) and donepezil (1 mg/kg, p. o.) 30 min before scopolamine (3 mg/kg), for seven days. Following treatments, behavioral (learning and memory) assessments were carried out, while biochemical (acetylcholinesterase activity, oxidative stress markers, inflammatory cytokines markers) and histological evaluations were done after euthanasia.

RESULTS:

Scopolamine significantly impaired spatial, long term and recognition memory. Nevertheless, administration of EECEL (50, 100, and 200 mg/kg orally) enhanced memory function in mice, as observed in the Y maze [F (5, 30) = 20.23, p < 0.0001], Morris water maze [F (10, 90) = 3.105, p = 0.0019; [F (5, 30) = 21.13, p < 0.0001]], and novel object recognition tasks [F (5, 30) = 37.22, p < 0.0001)]. Scopolamine-treated mice exhibited significant dysfunction in the cholinergic system, as evidenced by elevated AChE activity [0.099 ± 0.005 vs. 0.063 ± 0.004 mol/min/g] with an elevation in oxidative stress. On the other hand, administration of EECEL counteracted these consequences by reducing AChE activity, mitigating oxidative damage, reducing pro-inflammatory cytokines, and preventing degeneration of neurons.

CONCLUSION:

The results demonstrated that EECEL effectively mitigates scopolamine-induced memory impairment via an oxido-inflammatory mechanism and modulation of the central cholinergic system.

News (Medical) associated with Donepezil Hydrochloride

30 Jul 2024

·www.businesswire.com

New Study Describes a Functional, Aged, Human Cell-Based Platform That Examines the Contribution of Senescence in Alzheimer’s Disease Progression, and Response to Therapeutics

ORLANDO, Fla.--( BUSINESS WIRE )--Researchers from Hesperos and the University of Central Florida have developed a groundbreaking model using human induced pluripotent stem cell (iPSC)-derived cortical neurons to better understand and combat Alzheimer’s disease (AD). Their study, “ A functional aged human iPSC-cortical neuron model recapitulates Alzheimer’s disease, senescence, and the response to therapeutics ," has been published in the prestigious journal Alzheimer's & Dementia ® : The Journal of the Alzheimer's Association. doi.org/10.1002/alz.14044 AD affects an estimated 6.2 million Americans aged 65 and older, with projections suggesting this number could reach 14 million by 2050. Current treatments, such as acetylcholinesterase inhibitors and NMDA receptor antagonists, provide only temporary relief. The high failure rate of AD clinical trials highlights the need for a better understanding of the pathophysiology and drug mechanisms. The study addresses a critical challenge in Alzheimer’s research: the degeneration of cortical layers associated with cognitive decline. Despite substantial efforts to date, few current AD therapies are not disease-modifying. The team accurately reproduced key biological aspects of aging and senescence in a multi-cellular microphysiological system (MPS), also known as a Human-on-a-Chip. This new approach reveals how cellular aging, also known as senescence, contributes to disease progression and therapy resistance, providing researchers with an accurate, human platform to further understand the disease and potential therapeutics in a living context. Further, since other platforms at Hesperos, based on neurodegenerative diseases, have been accepted by the Food and Drug Administration (FDA) for efficacy data, it provides a new method to accelerate development and regulatory submissions of new treatments. This model provides an invaluable tool for real-time measurement of neuronal activity and aging biomarkers, facilitating drug screening and the development of AD therapies. It also reveals complex disease mechanisms, such as the role of inflammatory factors in neuronal senescence and how it differs from non-disease age-related controls, offering new targets for intervention. Researchers cultured human iPSC-derived cortical neurons on patterned microelectrode arrays to measure long-term potentiation (LTP) noninvasively. LTP, a quantifiable metric for learning and memory, is directly impacted by central nervous system neurodegeneration. By treating these neurons with pathogenic amyloid-β (Aβ), a peptide that plays a central role in development of AD, to mimic disease pathophysiology, the team was able to analyze senescence and therapeutic responses. The study demonstrates that this novel human iPSC-cortical neuron model of aging, cultured in serum-free, defined conditions, accurately recapitulates hallmarks of AD showing the following: Pathological Insights : Aβ42 induced synaptic damage, accelerated neuronal senescence, impaired mitochondrial potential, and increased reactive oxygen species (ROS), leading to oxidative stress and inflammation. Therapeutic Responses : Drugs such as memantine, rolipram, saracatinib, and donepezil improved neuronal function and viability, though they did not completely halt Aβ42-driven senescence. The study underscores the potential of biomimetic MPS systems in translational research. By integrating clinically relevant neuronal function with proteome responses, this platform is poised to accelerate the discovery of novel neuroprotective compounds for AD and other neurological disorders. “This marks a significant step forward in Alzheimer's research by providing a deeper understanding of AD pathophysiology in a human aged MPS platform. We are excited about the potential of this model to transform drug discovery in AD, providing hope for patients,” said J. Hickman, PhD, co-founder and Chief Scientist of Hesperos and Professor of Chemistry at UCF. This research was supported by grants from the National Institutes of Health (R44TR001326, R44AG058330). Research Article : doi.org/10.1002/alz.14044 Nanoscience Technology Center (NSTC) at the University of Central Florida (UCF) The mission of the NSTC is to establish a cutting-edge research program in materials and nanotechnology, provide high quality training for students and facilitate the advance of innovations to solve real world technology challenges. https://nanoscience.ucf.edu/ Hesperos, Inc. Hesperos is a global contract research organization (CRO) providing drug development services using its Human-on-a-Chip ® platform - the most advanced, multi-organ microphysiological systems available today. https://hesperosinc.com

11 Jul 2024

·www.drugs.com

New Research Points Towards Potential Treatment for Anorexia

THURSDAY, July 11, 2024 -- Anorexia nervosa could be caused by lack of a specific brain chemical, reports a research team that has developed a possible cure for the eating disorder . Mouse studies have revealed that a deficit in acetycholine, a neurotransmitter associated with the brain’s reward system, could be linked to excessive habit formation. This deficit could be behind the compulsive self-starvation seen in people with anorexia, researchers argue in the July 7 issue of the journal Nature Communications . The Alzheimer's drug donepezil , which increases acetylcholine, “fully reversed the anorexia-like behaviour in mice, and we believe that it could potentially offer the first mechanism-based treatment of anorexia nervosa,” said senior researcher Dr. Salah El Mestikawy , professor of psychiatry with McGill University’s Douglas Research Center in Montreal. “In fact, we are already seeing its effects on some patients with the disease,” El Mestikawy added in a McGill news release. Positive results have already been seen in 10 patients with severe anorexia who are being treated with low doses of donepezil, researchers said. Three patients are in full remission from anorexia, and the other seven have shown marked improvements, results show. Full-fledged clinical trials comparing donepezil against placebo in treating anorexia are set to start later this year at three major hospitals in the United States and France, researchers said. However, El Mestikawy cautioned that it could take several years before a new drug targeting anorexia receives government approval and becomes available to patients. Donazepil causes many gastrointestinal and muscle side effects, El Mestikawy said. Researchers are working to develop a new drug that boosts acetylcholine with fewer problems. “We also suspect that other compulsive pathologies such as obsessive-compulsive disorders (OCD) and addictions can also be improved by donepezil, so we are actively looking for collaboration with other psychiatrist around the world to explore the possibilities,” El Mestikawy added. Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.

05 Jul 2024

·healthcare-digital.com

Eli Lilly Alzheimer's Drug Kisunla Approved in US by FDA

Eli Lilly's donanemab drug is an early-stage Alzheimer's treatment that will be sold under the brand name Kisunla. Eli Lilly's treatment to slow early-stage Alzheimer's gets Food and Drug Administration approval, meaning US patients now have two treatments options The US Food and Drug Administration ( FDA ) has approved another treatment to slow early-stage Alzheimer's , meaning there is two treatment available to US patients experiencing early symptoms of the disease. The approval is for the drug donanemab, an antibody treatment made by Eli Lilly that will be sold under the brand name Kisunla. Reuters reports that FDA approval followed recommendations given by the agency's outside experts, who unanimously backed its use in patients with early-stage Alzheimer's disease, saying the benefits of the drug outweighed its risks. “This is real progress," said Joanne Pike of US-based Alzheimer’s Association. “Having multiple treatment options is the kind of advancement all who have been touched by this difficult and devastating disease have been waiting for.” The other existing early-stage treatment available in the US is lecanemab, made by Eisai and Biogen , and sold under the brand name Leqembi. This is administered intravenously every two weeks. Eli Lilly's donanemab 'slows memory loss' In Lilly's large, late-stage trial, donanemab slowed the progression of memory and thinking problems by 29% compared with a placebo. It also caused brain swelling in nearly a quarter of patients and brain bleeding in nearly a third, but most cases were mild. As it did for Leqembi, the FDA placed its strongest safety warning on donanemab's prescribing label, flagging the risk of potentially dangerous brain swelling and bleeding. A key differentiating factor of donanemab compared to Leqembi is the drug's ‘finite dosing’, which allows patients to stop taking the treatment once brain scans no longer show amyloid plaques, the cause of Alzheimer's symptoms. Amyloid plaques are rogue protein clusters invisible to the naked eye, that disrupt the brain's communication network. Over time, these plaques slowly poison nearby healthy brain cells and the body, sensing invasion, attempts to counteract this, with brain inflammation the result. This further harms delicate neural tissue. The Eli Lilly drug is on sale at $695.65 per vial – slightly more than Eisai's Leqembi, which costs $26,500 a year. Lilly's drug is expected to be used mostly by patients enrolled in the US government's Medicare health plan for people age 65 and older. Medicare last year began covering Alzheimer's drugs that receive standard FDA approval. As well as the two treatments for early-stage Alzheimer's, the FDA has approved drugs that temporarily mitigate some symptoms of Alzheimer's dementia. These include: Donepezil (brand name, Aricept), made by Eisai, improves attention and memory Rivastigmine (Exelon) is made by Novartis , and approved for mild-to-moderate Alzheimer’s and Parkinson’s disease. Galantamine (Razadyne), made by Janssen Pharmaceuticals, and designed to treat mild to moderate Alzheimer's disease.

Drug Approval

100 Deals associated with Donepezil Hydrochloride

External Link

KEGG	Wiki	ATC	Drug Bank
D00670	Donepezil Hydrochloride	N06DA02	DB00843

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Lewy Body Disease	JP	Eisai Co., Ltd.	19 Sep 2014
Alzheimer Disease	US	Eisai, Inc.	25 Nov 1996

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Cognitive Dysfunction	Phase 3	US	Pfizer Inc.	01 Sep 2008
Cognitive Dysfunction	Phase 3	US	Eisai, Inc.	01 Sep 2008
Down Syndrome	Phase 3	US	Pfizer Inc.	01 Sep 2008
Down Syndrome	Phase 3	US	Eisai, Inc.	01 Sep 2008
Attention Deficit Disorder	Phase 3	US	Eisai Co., Ltd.	02 Jul 2008
Attention Deficit Disorder	Phase 3	AR	Eisai Co., Ltd.	02 Jul 2008
Attention Deficit Disorder	Phase 3	AU	Eisai Co., Ltd.	02 Jul 2008
Attention Deficit Disorder	Phase 3	CA	Eisai Co., Ltd.	02 Jul 2008
Attention Deficit Disorder	Phase 3	CL	Eisai Co., Ltd.	02 Jul 2008
Attention Deficit Disorder	Phase 3	FR	Eisai Co., Ltd.	02 Jul 2008

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04730635 (MK-0000-413, CTgov)	Phase 1	Alzheimer Disease \| Mild cognitive disorder	44	Donepezil (Donepezil)	yxcbwevwab(qrssonbbyh) = fxjoeymryj wnekehfvpo (pdfyzhjsqz, dgvfxahmvr - aykialwcvx) View more	-	28 Oct 2024
				Placebo (Placebo)	yxcbwevwab(qrssonbbyh) = vvzmqomcie wnekehfvpo (pdfyzhjsqz, hqtlntexdv - ppvpvzgmto) View more
NCT04617782 (CTgov)	Phase 1	-	60	Donepezil (Treatment A 5 mg TDS)	wfjzrutsni(ihurojappv) = tkrdjavscs wdvzqibhqf (ezpijfcbfw, xcbbyyvbqx - dkycihofpp) View more	-	19 Sep 2024
				Donepezil (Treatment B 10 mg TDS)	wfjzrutsni(ihurojappv) = dyokflsqqb wdvzqibhqf (ezpijfcbfw, bdeujrmuhn - vyibtaefgf) View more
NCT02822573 (Remember, CTgov)	Phase 3	Cognitive Dysfunction \| Breast Cancer	276	Donepezil 5 mg (Donepezil)	akmpqyealu(nbdwrisimq) = gnpkvxxizw piqnzfsdfq (wciveblqta, lblebdmyff - wpudlcwyfc) View more	-	13 Sep 2023
				Placebo (Placebo)	akmpqyealu(nbdwrisimq) = iudnvxzeyz piqnzfsdfq (wciveblqta, livjwtgosg - xnhamteqln) View more
LIFE Study (AAIC2023)	Not Applicable	Alzheimer Disease First line	-	Newly prescribed donepezil	lwxnjsghkj(kxwphamccx) = gdufqokekf hgmnzeiqfa (hnjvcnjkga )	-	16 Jun 2023
AAIC2022	Not Applicable	Alzheimer Disease	-	Donepezil hydrochloride loaded chitosan nanoparticles	iipgakkzna(ekwtsjxxoq) = nlxsaqgsdn muptlokdcy (yupubuexmk ) View more	-	20 Dec 2022
NCT04617782 (Pubmed)	Phase 1	-	60	10-mg/d Corplex™ donepezil transdermal delivery system	sjwkxlylsw(qkjprrjxst) = oral donepezil was associated with higher incidence of gastrointestinal AEs (14.5% versus 53.6%) fpjzieudpe (kgtsbplnkx ) View more	-	16 Sep 2022
				5-mg/d Corplex™ donepezil transdermal delivery system
NCT04617782 (ANA2022)	Phase 1	-	-	Once-weekly 5-mg/d donepezil TDS	caovmqrttg(fpppbxjmlo) = combined skin irritation score of ≥ 3 reported in 51.7% and 54.5% of participants, 0.5 hours after 5- and 10-mg/d TDSs removal, respectively rscqzqzegu (mwclqxspdz )	-	14 Sep 2022
				Once-weekly 10-mg/d donepezil TDS
NCT04617782 (ANA2022)	Phase 1	-	60	Donepezil TDS 10mg/d	izemsyydxn(ejitvhzzsv) = mhixlgncca tavpvedidr (dnajzxqpmf, 100.5 - 117.4) View more	Positive	14 Sep 2022
				Donepezil TDS 5mg/d	izemsyydxn(ejitvhzzsv) = ofxsrjxzjm tavpvedidr (dnajzxqpmf, 97.6 - 113.6) View more
NCT00477659 (CTgov)	Phase 4	Alzheimer Disease	14	Donepezil hydrochloride	xpxmfxpzzj(zshfplnymh) = ohakabaysc fymkhegaed (kivhvoewbz, jyvcgpjdii - vqmpnhjtgz) View more	-	10 Nov 2021

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Chat with Hiro

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis